Ultragenyx Pharmaceutical Inc. (RARE) Deep Dive Video
Summary
Ultragenyx is a rare-disease commercial platform priced like a cash-burning biotech—its next re-rating depends on 2026–2027 gene-therapy execution and a potentially scale-changing Angelman Phase 3 readout.